Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity
Journal of Xenobiotics · 01.05.2024 · 14 (2) · 575-603
DOI: 10.3390/jox14020034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Xenobiotics, online erschienen am 01.05.2024. Verfasst von Isabel S Barata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Endocrinology, Diabetology and Metabolism, University Children's Hospital, University of Bern, 3010 Bern, Switz…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, European Commission, HORIZON-HLTH-2022-STAYHLTH-02.
Abstract (Originalsprache)
Progesterone receptor membrane component 1 (PGRMC1) is one of few proteins that have been recently described as direct modulators of the activity of human cytochrome P450 enzymes (CYP)s. These enzymes form a superfamily of membrane-bound hemoproteins that metabolize a wide variety of physiological, dietary, environmental, and pharmacological compounds. Modulation of CYP activity impacts the detoxification of xenobiotics as well as endogenous pathways such as steroid and fatty acid metabolism, thus playing a central role in homeostasis. This review is focused on nine main topics that include the most relevant aspects of past and current PGRMC1 research, focusing on its role in CYP-mediated drug metabolism. Firstly, a general overview of the main aspects of xenobiotic metabolism is presented (I), followed by an overview of the role of the CYP enzymatic complex (IIa), a section on human disorders associated with defects in CYP enzyme complex activity (IIb), and a brief account of cytochrome b5 (cyt b5)’s effect on CYP activity (IIc). Subsequently, we present a background overview of the history of the molecular characterization of PGRMC1 (III), regarding its structure, expression, and intracellular location (IIIa), and its heme-binding capability and dimerization (IIIb). The next section reflects the different effects PGRMC1 may have on CYP activity (IV), presenting a description of studies on the direct effects on CYP activity (IVa), and a summary of pathways in which PGRMC1’s involvement may indirectly affect CYP activity (IVb). The last section of the review is focused on the current challenges of research on the effect of PGRMC1 on CYP activity (V), presenting some future perspectives of research in the field (VI).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Endocrinology, Diabetology and Metabolism, University Children's Hospital, University of Bern, 3010 Bern, Switzerland.
- Translational Hormone Research Program, Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
- ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisboa, Portugal.
ORCID-Profile: Isabel S Barata, Michel Kranendonk, Francisco Esteves
Förderung
- Fundação para a Ciência e Tecnologia
- European Commission
- HORIZON-HLTH-2022-STAYHLTH-02
- Portuguese Fundação para a Ciência e a Tecnologia (FCT)
Zitieren
APA
Barata, I. S., Rueff, J., Kranendonk, M., & Esteves, F. (2024). Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity. Journal of Xenobiotics, 14(2), 575-603. https://doi.org/10.3390/jox14020034
Vancouver
Barata IS, Rueff J, Kranendonk M, Esteves F. Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity. Journal of Xenobiotics. 2024;14(2):575-603. doi:10.3390/jox14020034
BibTeX
@article{Barata2024,
author = {Barata, Isabel S and Rueff, José and Kranendonk, Michel and Esteves, Francisco},
title = {Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity},
journal = {Journal of Xenobiotics},
year = {2024},
volume = {14},
number = {2},
pages = {575--603},
doi = {10.3390/jox14020034}
}
EUVIMED